Hester Biosciences delivered exceptional Q4FY26 results with consolidated net profit surging to ₹165 crore from ₹1.2 crore in the year-ago period, representing a remarkable 10-fold year-on-year growth. According to latest reports, the profitability was significantly aided by a one-time gain of ₹29.4 crore from the divestment of a 43.81% equity stake in Texas Lifescience Pvt. Ltd., which ceased to be a subsidiary from March 27, 2026. Revenue demonstrated robust growth of 22% to ₹1,001.1 crore from ₹774.2 crore in Q3 FY26, while sequential growth from Q3's ₹749.8 crore showed strong operational momentum. The company's earnings per share rose sharply to ₹19.45 from ₹1.82 a year ago, reflecting improved profitability across all key metrics.
The poultry healthcare division emerged as the primary growth driver, with revenue increasing to ₹647.2 crore in Q4 from ₹480.2 crore in Q3 FY26, while animal healthcare revenue rose to ₹353.9 crore from ₹229.5 crore during the same period. Segment results for poultry healthcare climbed significantly to ₹231.1 crore from ₹135.2 crore in the previous quarter, benefiting from improved market penetration, expanded placements and sustained vaccine demand. The company also received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine during the quarter, a major addition to its poultry vaccine portfolio that addresses significant disease concerns and enhances competitive edge. Total expenses increased to ₹767.9 crore from ₹725.4 crore in the year-ago quarter, while the company maintained focus on poultry healthcare growth despite uneven demand across certain animal healthcare markets.
For the complete fiscal year FY26, Hester Biosciences achieved strong consolidated revenue growth of ₹3,326 crore compared to ₹3,111 crore in FY25, representing a 7% year-on-year increase. As reported by multiple sources, net profit nearly doubled to ₹574.8 crore from ₹288.3 crore year-on-year, with the strong profit growth significantly boosted by robust Q4 performance. The company's gross profit margins improved during FY26 due to a favourable product mix and continued operational discipline. The poultry healthcare segment remained the largest revenue contributor, adding ₹206 crore compared to ₹167 crore in FY25, while animal healthcare revenue declined to ₹126.6 crore from ₹143.6 crore a year ago. The company also significantly strengthened its balance sheet by reducing standalone non-current borrowings from ₹51.31 crore to ₹21.68 crore.
Following the strong results announcement, shares of Hester Biosciences jumped over 14% and were trading at ₹1,962, representing a 36% gain over the last one month. The company's board has recommended a dividend of ₹11 per equity share for FY26, representing 110% of face value, subject to shareholder approval at the upcoming annual general meeting. Ms. Priya Gandhi has been re-appointed as Executive Director for a three-year term, effective October 28, 2026, ensuring leadership continuity. The strong financial performance supports Hester's strategic initiatives, including expansion of its poultry healthcare portfolio and new licenses for the H9N2 Avian Influenza vaccine. The company strategically acquired Alivira Animal Health's India business for ₹26.5 crore in October 2023, enhancing its market footprint, while plans are underway to expand manufacturing capacity at its Gujarat facility.
